Category Archives: Parkinson’s Treatment

Despite immense gains in knowledge about the disease in recent years, scientists still do not know what causes it and have struggled to find a treatment that will stop its progression once and for all. But now a potential new drug being tested by a group of Chinese scientists and clinicians may offer a glimmer of hope, with promising results after it was used on a severely affected patient for six months. Continue reading →

A Voice Reclaimed: Parkinsons Patient Finds Hope in Adjusted DBS Treatment In a heartwarming Christmas tale, Bernard Parmenter, a 68-year-old former company director, regained his ability to speak, a gift he had lost to Parkinsons disease. The remarkable event unfolded when doctors successfully recalibrated electrodes implanted in his brain, a procedure known as deep brain stimulation treatment (DBS). The adjustment, performed last month, enabled Bernard to speak again, allowing him to express holiday greetings to his family for the first time in three years. Continue reading →

Black Americans make up 13.6% of the U.S. population. Yet only 1.7% of participants in Parkinsons disease (PD) trials are Black. Continue reading →

LAFAYETTE, Ind. Continue reading →

WATCH TIME: 3 minutes "There is a variety of experimental targets. I will start by saying that some of these targets are easily stimulated because they are in proximity of the approved targets." Introduced in the late 1940s, the use of deep brain stimulation (DBS) has evolved significantly over time and is now considered an effective alternative treatment for patients with Parkinson disease (PD). Originally, stimulation was predominantly being used to localize areas for selective brain ablation and as a method to avoid adverse events. Continue reading →

Exciting developments in the field of Parkinsons disease treatment have emerged, with recent research producing a method to develop highly pure dopamine cells from stem cells. Published in Nature Communications, the findings show promising results in restoring movement in animal models, offering potential side-effect-free and long-lasting treatment effects for Parkinsons disease patients. Continue reading →

The ancient exercise of tai chi has long been associated with better balance, stability, and moodbut two new studies show the practice may also provide major brain health benefits to older adults. The first study, published in the Annals of Internal Medicine, found that practicing tai chi may help improve cognition and memory concerns in people with mild cognitive impairment; the second, in the Journal of Neurology, Neurosurgery, and Psychiatry, showed that doing the exercise for an extended period of time could help slow the progression of Parkinson's disease. According to experts, its no surprise that the slow, controlled movements of tai chia workout for the body and mindcan benefit both physical and cognitive health. Continue reading →

Ground-breaking research conducted at Oxfords Nuffield Department of Clinical Neurosciences has led to the inception of a revolutionary new blood test, which could potentially identify the pathology that triggers Parkinsons disease before the manifestation of its main symptoms. Continue reading →

Recent findings in neuroscience and neurology have started to shed light on the intricate connections between personality traits, dementia diagnoses, Parkinsons disease, and multiple sclerosis. These understandings not only contribute to the scientific communitys growing knowledge of these complex conditions but also potentially pave the way for innovative treatment options. A recent meta-analysis revealed that personality traits are strong predictors of dementia diagnoses. Continue reading →

Gain Therapeutics, Inc. Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinsons disease Company is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023 Received a $2.8 million (CHF $2.5 million) grant from Innosuisse, the Swiss Innovation Agency, to advance the development of GT-02287 in GBA1 Parkinsons disease Obtained a grant in the aggregate amount of $1.3 million (EUR 1.2 million) to a consortium led by Gain Therapeutics for further development of the Companys novel small molecule allosteric regulators against Alpha-1 Antitrypsin Deficiency Appointed C. Continue reading →